- Viral vector manufacturing and cell line development are keystone applied sciences within the making of gene therapies
- 46 scientific consultants based mostly in Cologne, Germany, be part of the Cytiva group in the genomic medication house
- Cytiva prospects will have fast entry to applied sciences that remedy some of the biggest challenges in bringing gene therapies to sufferers
AMERSHAM, England, Oct. 6, 2022 /PRNewswire/ — Global life sciences chief Cytiva has acquired CEVEC Pharmaceuticals, a number one German supplier of high-performance cell line development and viral vector manufacturing applied sciences. CEVEC will additional strengthen Cytiva’s main place in biomanufacturing options.
Emmanuel Abate, President, Genomic Medicine at Cytiva, says: “Cevec’s innovative technology complements Cytiva’s offering and brings the promise of improved viral vector manufacturing. With Cytiva’s global reach and ability to scale, more customers will have access to Cevec’s technology and expertise to help accelerate and advance therapeutics for the benefit of patients.”
Dr. Nicole Faust, CEO of CEVEC Pharmaceuticals, says: “We are excited to become part of Cytiva. Combined with Cytiva’s global presence and leading brands, this enables the whole gene therapy industry to embark on new and powerful solutions for scalable vector manufacturing and start a new era for therapies made available to patients in need.”
One of the pharmaceutical trade’s greatest challenges in cell and gene remedy is establishing manufacturing processes that may sustain with the rising demand for quantity and constant high quality of viral vectors. With its scalable producer cell strains for vectors based mostly on Adeno- Associated Virus (AAV) and Adenovirus, CEVEC covers two of probably the most broadly used vectors for delivering therapeutic genes to focus on cells and tissues.
Producer Cell Lines (PCLs) as enabled by CEVEC’s ELEVECTA® Technology allow yield, scalability, and robustness within the manufacturing course of. With the ELEVECTA® Technology, all parts needed for vector manufacturing are stably built-in into the genome of the PCL, providing an alternative choice to applied sciences based mostly on transfection or using a helper virus.
CEVEC and its 46 scientific consultants will turn out to be a part of Cytiva with fast impact. CEVEC’s merchandise, providers and applied sciences will proceed to be provided underneath the ELEVECTA® and CAP® manufacturers within the fast future and can be accessible to prospects worldwide.
Follow Cytiva on LinkedIn and Twitter. For extra on CEVEC, go to right here.
Cytiva is a world life sciences chief that works with tutorial and translational researchers, builders and producers of biotherapeutics, cell and gene therapies, and new applied sciences akin to mRNA, to allow the supply of transformative medicines. Cytiva is a trusted skilled with practically 10 000 associates in additional than 40 nations devoted to prospects’ pace, flexibility, capability and effectivity in drug discovery, analysis, and manufacturing.
View authentic content material:https://www.prnewswire.co.uk/news-releases/cytiva-strengthens-cell-line-development-with-cevec-acquisition-301641861.html
